Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthF. Michael Yakes, Alison Joly|Molecular Cancer Therapeutics|2011Cited by 1.3k
Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signalingRongrong Ge, Michael Reiß, Gayathri Subramanian et al.|Biochemical Pharmacology|2004Cited by 38